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As the population ages and lifestyles change in concordance, the number of patients suffering from ischemic stroke and
its associated disabilities is increasing. Studies on determining the relationship between endothelial progenitor cells (EPCs)
and ischemic stroke have become a new hot spot and have reported that EPCs may protect the brain against ischemic
injury, promote neurovascular repair, and improve long-term neurobehavioral outcomes. More importantly, they introduce
a new perspective for prognosis assessment and therapy of ischemic stroke. However, EPCs’ origin, function, influence
factors, injury repair mechanisms, and cell-based therapy strategies remain controversial. Particularly, research conducted
to date has less clinical studies than pre-clinical experiments on animals. In this review, we summarized and analyzed the
current understanding of basic characteristics, influence factors, functions, therapeutic strategies, and disadvantages of
EPCs as well as the regulation of inflammatory factors involved in the function and survival of EPCs after ischemic stroke.
Identifying potential therapeutic effects of EPCs in ischemic stroke will be a challenging but an incredibly important
breakthrough in neurology, which may bring promise for patients with ischemic stroke.
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Ischemic stroke, also known as cerebral infarction, refers
to a local blood supply obstacle that leads to cerebral an-
oxic lesions and ischemic necrosis, which subsequently
causes a loss of corresponding neurological functions.
Although few effective therapies are available, it is ex-
ceptionally crucial that patients who experience the on-
set of an ischemic stroke take drugs that have been
implicated in providing effective cerebral protection and
repairing the blood supply of ischemic penumbra as
soon as possible. As the precursor cells of endothelial
cells (ECs), endothelial progenitor cells (EPCs) have the
characteristic of mobilization and can further proliferate
and differentiate into mature ECs. Under the stimulus of
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unless otherwise stated.derived EPCs can migrate to the peripheral blood where
they participate in the repair of damaged blood vessels
and angiogenesis in ischemic tissues. Recent studies on
EPCs provide novel and promising potential therapies
for the treatment of ischemic stroke and prognosis as-
sessment improvement. In the following overview, we
will elaborate regarding the role of EPCs in ischemic
stroke.Basic characteristics of EPCs in ischemic stroke
Source and measurement
Niches, or specialized microenvironments that support
the function of a specific cell, vary between cell pheno-
types. Specifically for stem cells, niches provide a pro-
tected compartment shielded from toxic agents where
stem cells can maintain their integrity and stemness but
where certain stimuli can initiate proliferation. After is-
chemic stroke, stem cells and EPCs are stimulated and
become mobilized in order to migrate from those niches.
Since the initially recognized niche of EPCs is the bone
marrow, many reports support that, after cerebral infarc-
tion, bone marrow-derived cells are a source of newlyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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indicates that EPCs can also be isolated and identified in
both peripheral blood and human cord blood [2-4]. Inter-
estingly, recent studies support that EPCs may particularly
reside in the adult vascular wall and be able to differenti-
ate into mature ECs [5], while c-kit + CD45− progenitor
cells derived from the liver can migrate to the peripheral
blood to supplement circulating EPCs [6]. This finding
not only strengthens our perception of the origin of EPCs
but also favors a shift away from the antiquated paradigm
that vasculogenesis occurs only during the process of em-
bryonic development. Additionally, EPCs can be cultured
in vitro from mononuclear cells isolated from peripheral
blood or bone marrow [7]. EPCs obtained from several of
the sources described above may be used to promote re-
covery after ischemic stroke in the future [1].
To measure circulating EPCs, they should be isolated,
identified, and quantified. As our previous studies demon-
strate, EPC populations can be better defined by analyzing
the surface markers expressed on the cells such as CD34,
CD133, and vascular endothelial growth factor receptor-2
(VEGFR-2, KDR) using flow cytometry; after that, the cells
have been positively stained. Additionally, functional EPCs
can also be isolated by utilizing a colony-forming unit
(CFU)-Hill, an endothelial colony-forming cells (ECFCs)
assay, or cell adhesion to fibronectin-coated dishes with
specific lectin and lipoprotein binding properties [8].
Nonetheless, the methodology of cell culture assays re-
mains popular. In the course of this approach, EPCs re-
main quiescent during the early stages of culture (within
48 h) but are quickly stimulated to proliferate and differ-
entiate into late EPCs or developed ECs (2 weeks), ultim-
ately generating cell products that can be analyzed based
on count and morphology [9]. Considering that the
markers of the progeny of ECFCs and ECs are nearly in-
distinguishable, we can further enrich the population of
ECFCs’ progeny by gating out monocytes, red blood cells,
dead cells, and CD45+ blood cells [10].Mobilization, migration, and differentiation
The ability of EPCs to repair ischemic injuries requires
them to first be mobilized in order for them to be able
to migrate into the ischemic region, where the EPCs can
then differentiate into mature ECs. These processes are
mediated mainly via growth factors which include, but
are not limited to, stromal-derived factor (SDF-1), VEGF,
granulocyte-colony-stimulating factor (G-CSF), stem cell
factor, soluble intercellular adhesion molecule, granulocyte-
monocyte-colony-stimulating factor, hepatocyte growth fac-
tor, interleukin-6 (IL-6), IL-10, estrogen, and endothelial
nitric oxide synthase (eNOS) [11]. Additionally, severe
forms of chronic brain hypoperfusion in intracranial ath-
erosclerotic disease (ICAD) might further stimulate themobilization of EPCs and angiogenic growth factor (AGF)
production [12].
The processes of EPC mobilization and migration are
influenced by several signal transduction pathways in the
cells. As shown in Figure 1, the first pathway, involving
SDF-1 and C-X-C chemokine receptor type 4 (CXCR4)-
mediated signaling [13-15], depends on the binding of a
ligand to its receptor. The majority of EPCs express
CXCR4. After ischemic stroke, SDF-1 expression in the
injured brain is remarkably up-regulated, while CXCR4
expression on EPCs is enhanced. The resulting increased
amount of SDF-1 in the brain attracts additional EPCs ex-
pressing CXCR4 to the ischemic region. Subsequently,
EPCs can then implement functions to augment the repair
of injured ECs, blood vessels, and even nerves. The medi-
ation of SDF-1/CXCR4 to EPCs also cooperates with
other growth factors such as VEGF/VEGFR [11], KDR/
CD34 [16], and G-CSF/stem cell factor (SCF) [17] and so
on. Figure 2 shows the second pathway: eNOS-dependent
signaling. It has been reported that most EPCs can express
eNOS, and that expression is increased following ischemic
stroke [18]. Up-regulated eNOS then promotes EPCs to
move to ischemic sites and subsequently raises the levels
of endogenous nitric oxide (NO) in the brain which can
dilate blood vessels, relax vascular smooth muscle cells,
increase blood flow, promote blood circulation, and regu-
late blood pressure and blood fat, ultimately inhibiting ath-
erosclerosis. Interestingly, a report showed that insulin-like
growth factor binding protein (IGFBP-3) could increase
the expression of eNOS, which may contribute to the acti-
vation of high-density lipoprotein receptor and the phos-
phatidylinositol 3-kinase/Akt pathway [19]. Moreover,
estrogens mobilize EPCs through an eNOS-mediated
mechanism as well as through direct actions on the alpha
and beta estrogen receptors via matrix metalloproteinase-9
(MMP-9) [8]. Taken together, this data indicates that
eNOS-dependent signaling also influences the migration of
EPCs.
Furthermore, insulin-like growth factor 2/mannose-6
phosphate (IGF2/M6P) receptor (IGF2R) is highly expressed
in EPCs, but its ligand, IGF2, which is a hypoxia-inducible
gene, is absent in the normoxic condition. However, cells
under hypoxic stress secrete IGF2 and subsequently in-
duce EPC chemotaxis through binding with IGF2R,
which can be inhibited by mannose-6-phosphate. The
effect of IGF2 on EPC chemotaxis is much stronger
than VEGF, which makes IGF2 similar to SDF-1. In
addition, IGF1 has an effect on EPC chemotaxis similar
to but relatively lower than that of IGF2 [20]. A study
has shown that IL-10 knockout (KO) mice reduce
myocardial-infarction (MI)-induced mobilization of bone
marrow EPCs, down-regulate the expression of CXCR4
and VEGF, and enhance the susceptibility to inflammation
or hypoxia-induced apoptosis, which can be reversed
Figure 1 SDF-1/CXCR4 and other factors work together to bring more EPCs to ischemic brain regions.
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inducible factor (HIF)-1alpha regulates the expression of
VEGF, SDF-1, and CXCR4, which can be up-regulated by
cobalt and hydralazine. Stabilizing HIF-1alpha protein en-
hances EPC mobilization and function [22]. EPC migra-
tion and adhesion can also be regulated by angiopoietin-2
(Ang-2), a soluble ligand on ECs at the sites of vessel re-
modeling and angiogenesis. Ang-2 causes a remarkable
stimulation of EPC migration, which can be inhibited by
soluble Tie2 (a receptor tyrosine kinase of the Tie family)
ectodomain, which binds Ang-2 as its ligand [23]. Similarly,
thrombin and its receptor, protease activated receptor-1
(PAR-1), could promote the mobilization, proliferation, and
differentiation of EPCs [24]. Another study showed that
retinal cells release neurotrophic factors under hypoxic
conditions to enhance EPC activity in vitro and increaseFigure 2 EPCs use IGFBP-3/eNOS/NO pathway to improve vessel dilation aangiogenesis in a mouse ischemic hind-limb model [25],
but whether they have the same role on EPCs after ische-
mic stroke is not yet established.
With regard to the differentiation of EPCs, except for the
above involved factors, VEGF can enhance the effects on
the differentiation from EPCs into mature endothelium,
which can be significantly promoted by fibronectin via spe-
cific synergism with alpha-5-beta-1 integrin [26]. Bone
morphogenic protein 4 (BMP4) is a specific marker of late
EPCs and plays a key role in EPCs’ commitment and out-
growth during neovascularization [27]. It has been well
established that cyclic-adenosine monophosphate (cAMP)
is an important secondary messenger in mediating many
physiological functions including cell differentiation. It has
been reported that in the mouse embryonic stem cells
system, 8-bromoadenosine 3′, 5′-cAMP(8-Br-cAMP, and blood supply to the ischemic areas.
Figure 3 Multiple pathways regulate EPCs homing to the
ischemic sites.
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tion of ECs [28]. A report indicated that mitogen-activated
protein kinase kinase (MEK, MAPKK)/extracellular signal-
regulated kinase (ERK) can modulate the fibrous tissue
remodeling in the periodontal ligament (PDL) by affecting
the proliferation, migration, and differentiation of the PDL-
derived EPC-like cells [29]. In a similar fashion, the issue of
whether this signal exists in the differentiation of EPCs after
ischemic stroke is not fully understood.
In conclusion, although the abovementioned growth
factors have been studied extensively, a more exact
mechanism still remains to be determined.
Homing
Pathways of homing
After ischemic stroke, the homing of EPCs to the neo-
vascular zone has been considered an essential step in
the formation of vascular networks, which involves the
interaction of many cytokines and their receptors. Some
specific pathways are as follows (Figure 3).
To illustrate one pathway, Biancone et al. [30] showed
that the homing of EPCs involves the expression of L-
selectin, an adhesion receptor on EPCs, and its ligand in
ischemic sites. Chavakis et al. [31] demonstrated in a
murine model of hind-limb ischemia that preactivation
of the beta-2 integrins expressed on EPCs via activating
antibodies enhances the homing and neovascularization
of EPCs in vivo. Moreover, Duan et al. [32] indicated
that leukocyte function-associated antigen (LFA-1,
alpha-L-beta-2, and CD11a/CD18) and integrin alpha-
4-beta-1 (very late antigen-4, VLA-4) expressed in hu-
man umbilical cord blood-derived high proliferative
potential-endothelial progenitor cells (HPP-EPCs) are
involved in HPP-EPCs homing to ischemic tissues via
the interaction with their ligands, intercellular adhe-
sion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), expressed in vessel endothe-
lium in ischemic tissues, which can be blocked by
CD11a and CD49d antibodies. Lev et al. [33] demon-
strated that platelets play a role in the homing of EPCs
to injury sites. The interaction between EPCs and acti-
vated platelets under static and flow conditions is
mediated through P-selectin-P-selectin glycoprotein
ligand-1 (PSGL-1) interaction in vitro, which is inhib-
ited by antibodies to P-selectin or PSGL-1, but not by
antibodies to glycoproteins Ib-IX-V or IIb/IIIa.
Additionally, Sbaa et al. [34] reported that EPC trans-
duction with caveolin small interfering RNA, which
mediates the endocytosis of CXCR4, regulating both
the SDF-1-mediated mobilization and peripheral hom-
ing of EPCs to ischemia sites, leads to a more extensive
rescue of the ischemic hind-limb. Chavakis et al. [35]
showed that EPCs express high-mobility group protein
B1 (HMGB1) receptors, including receptors foradvanced glycation end products (RAGE) and toll-like
receptor 2 (TLR2), but HMGB1 stimulates the migra-
tion of EPCs in a RAGE-dependent manner, where
HMGB1 increases EPC adhesion to the immobilized
integrin ligands, ICAM-1 and fibronectin. Besides,
HMGB1 rapidly increases integrin affinity and induces
integrin polarization. What is more, Maeng et al. [20]
reported that the remarkably promoting role of the
IGF2/IGF2R system in EPC homing is mainly via
IGF2R-linked G(i) protein signaling and intracellular
calcium (Ca2+) mobilization which is induced by the
beta-2 isoform of phospholipase C. Zhao et al. [36]
thought that sphingomyelin synthase 2 (SMS2) over-
expression is probably associated with an increase in
expression of aortic inflammatory biomarkers, as well
as a decrease in the number of CD34/KDR-positive
cells, circulating angiogenic cells (CACs), and CFU in
circulation in apolipoprotein E (ApoE) KO mice. What
is more, Shen et al. [37] indicated that the SDF-1alpha-
small GTPaseRAC signaling pathway plays an import-
ant role in polarity, morphology variation, and the
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1alpha. Finally, Wang et al. [38] showed that peroxisome
proliferator-activated receptor (PPAR)-alpha restrains
ischemia-induced EPC mobilization and homing via in-
hibition of the HIF-1alpha/SDF-1 pathway during retinal
neovascularization. Furthermore, chemokine (C-C motif)
ligand 5 (CCL5) induces in vitro EPC homing in a C-C
chemokine receptor type 5 (CCR5)-dependent manner.
The CCL5/CCR5 interaction will be a novel molecular tar-
get for modulation of neovascularization and eventual tis-
sue repair [39]. EPCs can express C-X-C chemokine
receptor type 2 (CXCR2), and damaged arterial smooth
muscle cells (SMCs) up-regulate the expression of chemo-
kine (C-X-C motif) ligand 7 (CXCL7) and CXCL1. The
binding between CXCR2 and CXCL1 or CXCL7 can also
enhance the homing of circulating EPCs to sites of arterial
injury and endothelial recovery in vivo [40]. E-selectin not
only stimulates ECs to express ICAM-1 but also EPCs to
secrete IL-8, leading to enhanced homing and incorpor-
ation of EPCs to ECs capillary formation [41]; the issue of
whether this process occurs after ischemic stroke remains
to be distinctly elucidated.
Enhancing homing efficiency
As mentioned above, EPC homing is crucial and poor
homing efficiency is one of the major limitations of
current EPC therapies. Hence, the issue of how to en-
hance EPC homing becomes particularly important. In
this aspect, the following addresses that recent research
has begun to make progress in EPC homing efficiency.
Wang et al. [42] found that one of the effects of
angiotensin-converting enzyme inhibitor, enalapril, on
the cardiovascular system involves the modulation of
levels of circulating EPCs by the CD26/dipeptidyl pep-
tidase IV (DPP-IV) system. In the blood, through the
anti-inflammatory effect, enalapril significantly decreases
CD26+ cell numbers then leads to a decrease in total
DPP-IV activity. However, in the bone marrow, enalapril
does not influence CD26+ cell numbers, but it does en-
hance DPP-IV activity. Evaluated results about a novel
strategy using magnetic bionanoparticles (MPs) to en-
hance the homing of transplanted EPCs to ischemic tis-
sue showed that below threshold concentration, MP
transfer can enhance the migration and homing without
influencing proliferation or survival of EPCs, in which
the effect of high dose MP is better than that of low
dose MP [43]. Georgescu et al. [44] have shown that the
treatment with angiotensin II receptor antagonist, irbe-
sartan, significantly increases EPC infiltration and de-
creases MP infiltration by diminishing pro-inflammatory
endothelial cytokines such as VEGFR-1, VEGFR-2, CXCR4,
Tie2, and placental growth factor with role in EPC homing
to sites of damaged endothelium, as well as by increasing
protein expression of cyclooxygenase 2 and prostacyclinsynthase molecules with a role in the improvement of arter-
ial wall vasodilatation.
In brief, although the roles of these cytokines and their
ligands on the homing of EPCs has been indicated by
many studies, it is still important to further improve our
understanding on the exact mechanism regarding the
homing of EPCs in order to enhance EPC homing effi-
ciency following ischemic stroke.
Immune phenotypes
Many studies have indicated that circulating EPCs cannot
only express human stem cell markers such as CD34,
CD45, CD62, or CD133 but can also express endothelial
cell markers such as CXCR4, CD31, VEGFR-2 (KDR or
Flk1), Von Willebrand factor (vWF), vascular endothelial
cell-Cadherin, Tie2, or eNOS [18], which participate in
maintaining the vascular homeostasis by monitoring and
repairing dysfunctional endothelium [16,45-47]. Moreover,
it has been reported that Flk1/CD34-double-positive EPCs
can express pro-recovery mediators such as the brain-
derived neurotrophic factor and basic fibroblast growth
factor [48]. Additionally, Brea et al. [49] indicated that
reticulum protein-29 and cell division control protein 42
homolog are only expressed in EPCs from healthy subjects,
whereas elongation factor-2 is only identified in EPCs from
ischemic stroke patients. Currently, more studies investi-
gating immune phenotypes of EPCs are under way.
Time distribution
Identifying the specific time distribution of EPCs after
ischemic stroke will guide us to conduct assessments of
EPC therapy. Firstly, in animal experiments, a report
using rats showed that EPCs are transplanted after a 90-
min middle cerebral artery occlusion (MCAO), and
myeloperoxidase-immunoreactive cell counts and neuro-
logical deficit scores are reduced after 24 h; the result
presents an increase in regional cortical blood flow and
a decrease in infarct volume after 48 h [18]. Secondly,
the study about patients with first episode of nonlacunar
ischemic stroke has reported that serum levels of VEGF
at 72 h and SDF-1alpha levels at 24 h are independent
factors of EPC increase during the first week of evolu-
tion of the disease [50]. Furthermore, in clinical trials,
Zhou et al. [51] showed that in Chinese patients with
acute stroke, EPCs gradually increase by day 7 after
acute onset, remain elevated by day 14, and return to
baseline by day 28. It is valuable for us to determine the
severity of human EPC changes following ischemic
stroke as time advances.
Influence factors of EPCs in ischemic stroke
It is well known that many factors contribute to the occur-
rence of cerebrovascular diseases such as high blood pres-
sure, heart disease, diabetes, dyslipidemia/hyperlipidemia,
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stenosis, hyperhomocysteinemia/high homocysteine, high
fibrin, lack of physical exercise, unbalanced diet, and so
on. Recently, more and more studies have begun paying
closer attention than previous reports had to these risk
factors as well as the correlation of EPCs in ischemic
stroke.
Negative factors
Atherosclerosis is one of the conventional risk factors of
cerebrovascular diseases, mainly on account of the vas-
cular stenosis caused directly by ruptured atheroscler-
osis and the embolism of distant small blood vessels due
to plaque falling off. Intracranial atherosclerotic disease
is an important cause of ischemic stroke, and endothe-
lial dysfunction plays a critical role in its onset and
progression [12]. In ApoE-deficient mice, repairing
functions of EPCs are weakened, which is correlated
with atherosclerosis caused by the chronic stimulation
of hyperlipidemia. C-reactive protein (CRP) causes a
concentration-dependent increase in reactive oxygen
species (ROS) and apoptosis, as well as a decrease in
glutathione peroxidase. Oxidized low-density lipopro-
tein induces apoptosis and senescence of EPCs. Carba-
mylated low-density lipoprotein induces an increase in
oxidative stress and mitochondrial depolarization and a
decrease in EPC proliferation and angiogenesis [8]. All
aspects mentioned above participate in the development
of atherosclerosis, which also suggests that the reduc-
tion of circulating EPCs may contribute to the develop-
ment of atherosclerosis and, in turn, enhancing EPCs
may reduce the injury of atherosclerosis by protecting
and repairing the damaged vascular functions [52].
Moreover, a high Hcy level in peripheral blood, as an in-
dependent risk factor, leads to vascular injury independ-
ently or synergistically with other risk factors, which
can contribute to atherosclerosis and then cause an is-
chemia. It has been observed that there is an inverse
correlation between EPC levels and Hcy levels, which
can be reversed by B vitamin intervention. Mediated by
high Hcy, EPC toxicity mainly involves apoptosis that
may refer to the activation of caspase-8 and caspase-9,
cytochrome C release, and caspase-3 activation [53].
Endothelin (ET) has been found so far to be the stron-
gest substance involving the shrinkage of blood vessels.
It can cause vasoconstriction, myocardial ischemia,
metabolic disorders, and cell proliferation, which are all
common risk factors of vascular injury-related diseases
including ischemic stroke. ECs have been shown to re-
flect the degree of endothelial damage, as they may be
responsible for increased ET-1 expression, which may
further play a role in the pathophysiology of stroke and
subsequent EPC mobilization [54]. It has been reported
that circulating EPCs are inversely correlated withparameters such as blood glucose levels and ischemic
damage, except for cerebral microvascular density in
diabetic stroke. In addition, cellular membrane micro-
particles impair EPCs’ functions [55]. According to the
report, we can postulate that increasing EPCs’ gener-
ation, improving EPCs’ function, and reducing produc-
tion of cellular membrane microparticles may attenuate
ischemic damage. In early ischemic stroke, EPCs and
markers of neuroinflammation that include up-regulated
adhesion molecules such as ICAM-1, VCAM-1, E-selectin,
tumor necrosis factor (TNF)-alpha, IL-6, ET-1, and
markers of tissue injury including MMP-9 and tissue in-
hibitor of matrix metalloproteinases-1 (TIMP-1) have a
negative correlation [56]. Body mass index, blood pressure,
LDL, total cholesterol, and high-sensitivity C-reactive pro-
tein also have an inverse correlation with EPC levels
whereas systolic blood pressure and total cholesterol are
independent predictors of EPC levels [51]. Tobacco smok-
ing, high fat diet, hypertension, and hyperlipidemia remain
as the major risk factors, and treatment of these conditions
has been shown to significantly reduce the incidence of is-
chemic stroke [57].Positive factors
Hayakawa et al. [58] have shown us that reactive astro-
cytes could promote proliferation of EPCs and then im-
prove neurovascular remodeling and functional recovery
after ischemic stroke. An important molecular mechan-
ism is as follows: reactive astrocytes release a damage-
associated molecule known as HMGB1 and up-regulate
HMGB1 in the peri-infarct cortex after ischemic stroke,
which can raise EPC levels, and then increase peri-
infarct angiogenesis to reduce the worsening of neuro-
logical deficits. Hayakawa et al. [48] further indicated
that the pathway of astrocyte-EPC signaling might im-
prove the recovery of white matter injury by enhancing
the functions of EPCs such as migration, accumulation,
and tube formation, which, however, is also dependent
on HMGB1 from reactive astrocytes and its receptor
RAGE. In addition, a recent study has shown that
erythropoietin (EPO) therapy can astoundingly enhance
the levels of circulating EPCs and improve 90-day major
adverse neurological event (defined as recurrent stroke,
National Institutes of Health Stroke scale is equal to or
more than 8, or death) through a randomized clinical
controlled trial [16,59]. As a subset of lymphocytes, an-
giogenic T-cells are able to stimulate EPC function [60].
Liu et al. [25] reported that neurotrophic factors may
promote the activation and mobilization of EPCs along
with subsequent neoangiogenesis. Moreover, IGFBP-3
prevented vascular endothelial cells and EPCs from
undergoing apoptosis [19]. A report has shown that
stem cells, including EPCs, from a variety of sources can
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to ischemic stroke [57].
Controversial factors
Angiotensin-converting enzyme 2 (ACE2) catalyzes the
conversion of angiotensin I (Ang I) into Ang 1–9 and Ang
II into Ang 1–7. It has been reported that Ang II down-
regulates circulating EPC levels, impairs EPC function, and
is detrimental to ischemic stroke in vivo and in vitro [61].
Furthermore, additional reports showed that ACE blockers
and type 1 angiotensin receptor inhibitors protect EPC sur-
vival and functions [62,63]. However, Chen et al. [64] indi-
cated that ACE2 could promote the migration of EPCs and
tube formation, improve their function, and enhance the ef-
ficacy of EPC-based therapy for ischemic stroke based on
the results from the in vivo and in vitro studies, which are
mainly via regulating eNOS and nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase (NOX) pathways.
Additionally, it has been put forward that ACE2 overex-
pression in blood vessels not only enhances the function of
ECs [65] but also limits the early development of athero-
sclerotic injury by improving ECs’ function [66]. The previ-
ously stated relationship is further supported by a finding
that ACE2 overexpression promotes the migration of EPCs
and tube formation, which can be enhanced by NOX in-
hibitor and inhibited by ACE2 or eNOS inhibitor [64].
Taken together, EPC levels are inversely correlated with
the various risk factors and positively correlated with astro-
cytes, EPO, and angiogenic T-cells, whereas the relationship
of ACE2 and EPCs still remains controversial. In spite of
the above ideas, by inhibiting negative factors and improv-
ing positive factors, it continues to be unclear whether or
not EPCs play a positive role in ischemic stroke.
Functions of EPCs in ischemic stroke
In recent years, EPCs have gained more and more atten-
tion, particularly regarding the relationship between EPCs
and ischemic cerebral diseases. EPCs carry out basic activ-
ities within the vascular system such as paracrine signaling,
healing of endothelial injury, and formation of new blood
vessels in ischemic tissue. It has also been found that EPCs
may play a critical role in the pathophysiology as well as tis-
sue repair and regeneration in the ischemic brain [13,67].
EPCs repair damaged ECs
It is well known that a major pathophysiological event of is-
chemic stroke is vascular endothelial damage that is in-
duced by various high-risk factors such as hypertension,
hyperlipidemia, diabetes, and many more. Evidentially, the
development of therapeutic approaches to repair damaged
ECs has become an attractive topic of research. After ische-
mia, EPCs migrate from the bone marrow to the injured re-
gion in order to repair the damaged site either through
direct incorporation of EPCs or by repopulating matureECs [53]. Increasing numbers of investigators recognize
that EPCs participate in endothelial repair with the follow-
ing probable mechanisms: the first theory proposes that
EPCs have an ability of differentiating into ECs, which can
add to the levels of circulating ECs that may be transported
to injured parts via blood flow to replace the injured ECs
[7,68]. In controversy, the second theory proposes that
EPCs can secrete protective cytokines and growth factors.
On one side, these factors may promote self-repair of in-
jured ECs, while on the other side, they may mediate
neighboring-injured ECs with normal structure and func-
tion extending into injured sites and performing the func-
tion of repair [7,45,68]. The above viewpoints have been
generally accepted, but the precise role of EPCs still re-
mains unclear (Figure 4).
EPCs promote the formation of new blood vessels
It has been reported that EPCs promote neurovascular
remodeling and functional recovery after stroke and brain
injury [58]. Several initial studies seem to support the con-
cept that postnatal new vessels rely on angiogenesis or the
process of forming new blood vessels from the existing ca-
pillaries or post-capillary venule [7,68]. As reports about
EPCs gradually increase, researchers have come to realize
that bone marrow-derived EPCs are not restricted to
angiogenesis and are also involved in vasculogenesis after
stroke [3]. Much like embryonic angiogenesis, vasculogen-
esis refers to the identification, mobilization, migration,
adhesion, and endothelial differentiation of EPCs, and in
particular, they may promote the formation of new vessels
in sites without blood vessels such as areas of ischemic
necrosis. Zhang et al. [69] obtained bone marrow-derived
EPCs from transgenic mice that expressed beta-
galactosidase regulated by an endothelial-specific Tie2
promoter and injected them into adult mice. The authors
discovered enlarged and thin-walled blood vessels with
sprouting or intussusception at the boundary of the ische-
mic injury, and that Tie2-lacZ-positive cells were incorpo-
rated into sites of neovascularization at the border of the
infarct, which exhibited an endothelial antigenic marker
known as vWF. In a way, these findings confirm the idea
that EPCs promote the repair and regeneration of injured
vessels simultaneously, which refers to the combined ac-
tion of angiogenesis and vasculogenesis after ischemic
stroke [70].
EPCs promote injured nerve repair
Patients with ischemic stroke appear to have neuronal in-
jury and necrosis, which give rise to changes in cognitive
behavior. Promoting the repair and regeneration of injured
nerves is also one of our therapeutic strategies. It is re-
ported that 4 weeks after transient MCAO, the transplant-
ation of EPCs reduces mouse cortex atrophy and improves
neurobehavioral outcomes [13]. The specific mechanisms
Figure 4 Mechanisms of EPCs repairing damaged ECs. 1. EPCs differentiate into mature ECs that repopulate injured sites; 2. Direct incorporation
of EPCs; 3. EPCs can secrete protective cytokines that can promote self-repair of injured ECs (3.1) or mediate neighboring-injury ECs with normal
structure and function to extend into injured sites and then perform the function of repair (3.2).
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of vessel growth factors results in neurogenesis and the
migration of neuroblasts to the peri-ischemic cortex
[71], which mainly refers to the proliferation and mi-
gration of subventricular zone neural progenitor cells
along with a shift in cell fate to neurogenesis and oligo-
dendrogliosis [72]. Additionally, EPCs may attenuate
cell injury through various functions such as blocking
neuronal apoptosis and oxidative stress. The detailed
mechanisms involve up-regulating Bcl-2 expression,
down-regulating expression of caspase-3, Bax, nuclear
factor (NF)-kappa-B, and malondialdehyde (MDA) in
the ischemic penumbra, which remarkably enhance ac-
tivities of superoxide dismutase (SOD), glutathione
(GSH), and glutathione peroxidase (GSH-PX) [73]. Fur-
thermore, EPCs participate in endothelial repair and
promote neurovascular formation, which could provide
a good, nutrient-rich microenvironment for nerve re-
pair, and reduce the cerebral infarct volume (Figure 5).
EPCs evaluate the prognosis of ischemic stroke
It has been found that the levels of circulating EPCs are
independently predictive of prognosis of ischemic stroke
[74]. Following acute ischemic stroke, circulating EPCs
are remarkably increased in order to execute their repair
function on cerebrovascular trauma. Moreover, the in-
crease of EPCs is associated with better functional out-
come and a reduction of infarct growth [75]. However,low circulating EPC levels are independently predictive
of severe neurological impairment measured at 48 h
after ischemic stroke, but as time proceeds, major ad-
verse clinical outcomes are fairly dynamic [74]. Further-
more, EPCs have different subsets such as the CFU and
the population of outgrowth cells. We can evaluate the
function of EPCs through the number and appearance
of CFU, to then evaluate the prognosis of ischemic
stroke [76]. Interestingly, a decrease of circulating EPCs
with subsequently impaired EC repair can reduce arter-
ial elasticity, which is a hallmark of aging in healthy
humans.
Altogether, EPCs may protect the brain against ische-
mic injury, promote neurovascular repair, improve
long-term neurobehavioral outcomes, and assist the
evaluation of prognosis of acute ischemic stroke. How-
ever, it presently remains unclear, referring to the cor-
relation between angiogenesis and neurogenesis, how
to measure EPCs’ quantity, quality, and properties, and
how to comprehensively evaluate the prognostic values
of EPCs on ischemic stroke.
Therapy
Considering the previously described functions of EPCs,
EPC-based treatment of ischemic stroke has become a
novel therapeutic strategy [2,77]. Importantly, the level
of EPCs in vivo is slender and limited, comprising just
less than 0.0001% to 0.01% of the peripheral circulating
Figure 5 Mechanisms of EPCs promoting nerve repair.
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EPCs as a therapy are valuable to develop. Current re-
searches have put forward a dichotomy of strategies which
includes an expansion of bone marrow-derived EPCs
in vivo and in vitro [18], however, although the former is
optimal, administration of in vitro-expanded EPCs is more
practical and feasible.
In vivo
Consequently, the main aspects are as follows: in terms
of physical therapy, it has been reported that electroacu-
puncture of the specific acupoints known as “Quchi”
and “Zusanli” can up-regulate levels of EPCs from per-
ipheral blood and bone marrow, serum total NOS activ-
ities, VEGF levels, blood CXCR4+ cells, as well as blood
SDF-1alpha protein content in cerebral ischemia/reper-
fusion injury rats, which may help alleviate injury, pro-
mote neovascularization, and improve cerebral ischemia
[78-80]. Moreover, voluntary physical activity improves
long-term stroke outcome by eNOS-dependent mecha-
nisms related to improving angiogenesis and cerebral
blood flow [81]. In terms of drug therapy, firstly, circu-
lating EPC levels may increase after statin treatment,
which is most likely related to NO, although it is still
unclear [82]. Secondly, B-type natriuretic peptide (BNP)
is a neurohormonal peptide that applies to treat chronic
heart failure patients. However, Shmilovich et al. [83]
tested that by enhancing the number, proliferation, adhe-
sion, and migration of EPCs, BNP could promote angio-
genesis, therefore making its therapeutic effect on
ischemic stroke promising. Thirdly, phosphodiesterase
III inhibitors, such as cilostazol, can increase circulating
EPCs, promote migration and adhesion of human umbil-
ical cord blood-derived EPCs to a fibronectin-coated
plate and ECs, and decrease small-dense LDL aftercerebral ischemia, which may be associated with indu-
cing integrin expression and activating protein kinase A
(PKA) and multi-purpose cAMP targeted (Epac) signals
[84,85]. Finally, based on a clinical controlled trial,
Sobrino et al. [86] found that a single administration of
cytidine diphosphate-choline (CDP)-choline and the co-
administration of CDP-choline and tissue-plasminogen
activator (rt-PA) both increase the levels of EPCs in
acute ischemic stroke, where the impact of the former is
miniscule, but the latter is remarkable. Therefore, it is
worthy to distinguish which effect occurs as a result of
CDP-choline alone versus the co-administration of
CDP-choline and rt-PA.
In vitro
The process of EPC expansion in vitro has many ap-
proaches and effects. For example, autologous EPCs
collected via a multiplication culture in vitro can then
be re-injected into the same animal. Transfusion of
lentivirus-ACE2-primed EPCs reduces cerebral infarct
volume and neurological deficits and increases cerebral
microvascular density and angiogenesis [64]. Moubarik
et al. [4] demonstrated that ECFCs injected 24 h after
MCAO settle in the injured area and improve func-
tional recovery. Another study has shown that during
the acute phase of cerebral infarction in rats, EPCs
with low aldehyde dehydrogenase activity (Alde-Low
EPCs) can be up-regulated and migrate into the infarct
region, accompanied with a decrease of infarct volume
[14]. The transplantation of Alde-Low EPCs naturally
provides a new strategy for patients that have suffered
acute cerebral infarction. What is more, colony-
outgrowth endothelial cells (OECs) from stroke pa-
tients are a subtype of EPCs which, at an early stage,
present higher levels of pro-angiogenic factors such as
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forming growth factor beta receptor 1, TNF-alpha-induced
protein 2, TNF, and TGF-beta-1; whereas mature OECs
present an increase in brain-specific angiogenesis inhibitor
1, neuropilin 2, thrombospondin 1, MMP2, and VEGF-C
expression [87,88]. Despite changes in angiogenic-related
gene expressions of OECs in the progress of expansion, the
pro-angiogenic potential is always kept intact. Therefore, it
would be beneficial to improve the cell-based therapy by
intervening at the stage of EPC differentiation and to test
autologous transplantation of EPCs using corresponding
markers at different stages.
Moreover, recent studies about human-induced pluripo-
tent stem cells (hiPSCs) put forward a new promise for
the treatment of EPCs in ischemic stroke. One study in
particular demonstrated that hiPSCs can differentiate into
many cell types including endothelium, which can exhibit
the rich functional phenotypic plasticity of mature pri-
mary vascular endothelium [89]. IPS cells are initially de-
rived from fibroblasts and are then reprogrammed into
partial iPS (PiPS) cells, and then into iPS cells using the
transcription factors Oct4, Sox2, Klf4, and c-Myc (OSKM)
or Oct4, Sox2, Lin28 and Nanog (OSLN). PiPS cells and
iPS cells can differentiate into fetal liver kinase-1 (Flk1/
KDR)-expressing cells and Islet-1 (Isl1)-expressing cells
and then directed to ECs. PiPS cells can be enhanced by
activin A, BMP-4, basic fibroblast growth factor, VEGF,
and Dickkopf homolog 1. Worthily, CD34+ EPCs that can
further differentiate into ECs to contribute to neovasculo-
genesis in ischemic regions could be derived from hiPSCs
via the inhibition of MEK/ERK signaling and the activa-
tion of BMP-4 signaling. Moreover, iPS cells can differen-
tiate into neural stem cells (NSCs) and neural crest stem
cells (NCSCs) for neural tissue regeneration, improved by
neural growth factor (NGF) and the inhibition of TGF-
beta receptors and SMAD (mothers against decapentaple-
gic homologs, signal transducers, and transcriptional
modulators that mediate multiple signaling pathways) sig-
naling [90]. In addition, hiPSC-ECs purified based on posi-
tive expression of CD31 are heterogeneous in nature,
displaying arterial, venous, or lymphatic subtypes, which
are enriched respectively by high VEGF-A concentration
and 8Br-cAMP, low concentration of VEGF-A, and
VEGF-C or angiopoietin-1. Particularly, arterial hiPSC-
ECs can form a more extensive capillary network in vivo
[28]. In general, though hiPSC-ECs provide a novel no-
tion, their scientific and therapeutic potential still remain
to be carefully assessed in clinical application (Figure 6).
Furthermore, the transplantation of EPCs, together with
other factors, may be more favorable since the endothelial
differentiation of CD34+ cells in co-culture with CD34 +
−derived ECs may decrease the inflammatory reaction and
increase the neovascularization of ischemic tissue [91]. It
has been reported that the NSCs and EPCs can ultimatelypromote each other by migrating to the injured sites follow-
ing ischemic stroke and inducing the neurogenesis and vas-
culogenesis of the local microcirculation [92]. An additional
study showed that the transplantation of both BMSCs and
EPCs provides an improvement in function, an increase in
microvessel density, and a decrease in apoptotic cells and
infarct volume of the ischemic boundary area [93]. Inducing
bone marrow-derived angiogenesis with the treatment of
G-CSF/SCF may improve neuronal survival and functional
outcome [17,94]. However, co-culture of EPCs with vascu-
lar SMCs increases the expression of the mesenchymal cell
markers such as alpha-smooth muscle actin, sm22-alpha,
and myocardin, as well as decreases the expression of
CD31 on ECs by means of an endothelial-to-mesenchymal
transition (EnMT)-like process [8].
Without doubt, the cultured quality of EPCs in vitro
cannot be ignored. Recently, Masuda et al. [95] investi-
gated the therapeutic potential of peripheral blood mono-
nuclear cells (PBMNCs), based on the quality and
quantity (QQ) culture of EPCs, and showed that the effi-
cacy of QQMNCs is superior to that of PBMNCs, early
EPCs, and CD34+ cells mobilized by G-CSF, regardless of
the methodology used, which included intramuscular
transplantation, the blood perfusion recovery, histological
evaluations, or quantitative reverse transcription and poly-
merase chain reaction assays in ischemic hind-limbs.Disadvantages
Nonetheless, as predicted, EPC-based treatment also con-
tains negative aspects. To begin with, therapeutic strategies
may be relatively difficult to administer. Recent studies have
shown that, compared with the controls, injected bone
marrow mononuclear cells after an induced hind-limb is-
chemia in ApoE−/− mice not only display an increased
neovascularization in ischemic regions but also promote
atherosclerotic plaque formation and enhance injury to the
area at the same time. In addition, EPC-treated mice also
display accelerated atherosclerosis along with reduced
plaque stability [8]. Moreover, an excessive treatment based
on EPCs may lead to abnormal intimal hyperplasia. Decano
et al. [96] reported that pro-angiogenic genes not only en-
hance intimal hyperplasia but are also involved in the pre-
disposition of age-associated intimal hyperplasia, which
may lead to vascular stenosis and then a vicious downward
spiral. Furthermore, the isolation process of autologous
EPCs inadvertently increases the burden of patients who
will be treated with EPCs, in terms of both medical inva-
siveness and financial costs [95]. However, Wang et al. [97]
have suggested that Ang-1-EPCs can express lower levels of
proliferating cell nuclear antigen and can inhibit neointimal
hyperplasia, compared to controls. Therefore, an appropri-
ate evaluation of the pros and cons of EPC-based therapy
still remains unknown.
Figure 6 Induced pluripotent stem cells may be used as novel therapies for neovasculogenesis and ischemic stroke.
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wide field of cell-based angiogenic therapy for ischemic
stroke, whereas, it still requires further studies in order
to identify the type of EPCs with the greatest thera-
peutic potential to be able to then formulate a detailed
treatment plan.
The regulation of inflammatory factors in improving the
function and survival of EPCs
Pathways of regulation
Although many studies have shown that EPCs have a
therapeutic effect on ischemic stroke, a major challenge
in translating this promise into clinical reality is our abil-
ity to efficiently deliver EPCs to target tissues and main-
tain a high viability and functionality. Still, the release of
inflammatory factors may compromise the therapeutic
efficacy; therefore, the regulation of these factors is
important. Specific regulating pathways are as follows
(Figure 7).
Firstly, Fan et al. [98] found that IL-6, whose receptor
(gp-80) is expressed in EPCs, stimulates EPC prolifera-
tion, migration, and matrigel tube formation in a dose-
dependent manner. In addition, the administration of
IL-6 can activate receptor gp80/gp130 signaling path-
ways including downstream ERK-1/2 and signal transducer
and activator of transcription-3 (STAT3) phosphorylationin EPCs. Thrombin is also a potent inflammatory factor,
which can combine the functional PAR-1 that is a
thrombin receptor, expressed on EPCs. What is more,
Smadja et al. [99] showed that activated PAR-1 induces
IL-8 synthesis from late EPCs, which involves activating
protein-1 (AP-1) and NF-kappa-B pathways. Besides,
Balestrieri et al. [100] unveiled a new inflammatory
pathway indicating that early EPCs can express platelet-
activating factor receptor (PAFR) and respond to PAF
via the signaling of a transient increase of cytoplasmic
Ca2+ concentration, which can be stimulated by TNF-
alpha or high-glucose levels. PAF (more than 50 ng/ml)
can reduce levels of EPCs with an increase of p38 activ-
ity, which can be abolished by a PAF receptor antagonist
such as CV3988. Moreover, Cuccuini et al. [101] showed
us that EPC-based therapy may be associated with pro-
thrombotic risk. In proinflammatory conditions, tissue
factors (TFs), which can trigger coagulation in ECFCs,
are up-regulated in response to TNF-alpha, which con-
fers to ECFCs a recombinant factor VII(a)-dependent
thrombin generation activity without influencing their
non-coagulant properties. Krishnamurthy et al. [21] in-
dicated that mobilization of EPCs following MI is im-
paired in IL-10 KO mice; conversely, IL-10 increases
the survival and function of EPCs, possibly through ac-
tivating STAT3/VEGF signaling pathways, to further
Figure 7 Inflammatory pathways can be regulated as therapeutic approaches for improving the function and survival of EPCs.
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remodeling. However, whether the above process oc-
curs in ischemic stroke has yet to be explored. Further-
more, Desouza et al. [102] thought that a chronic
inflammatory environment can cause insulin signaling
defects in EPCs to reduce their survival, which can be
reversed by modifying EPCs with a knockdown of NF-
kappa-B. Additionally, modifying EPCs also decreases
neointimal hyperplasia in Zucker fatty rats. This evidence
suggests that inflammatory and oxidative changes can
increase apoptosis of EPCs, of which TNF-alpha plays
a key role as an inflammatory mediator and an inducer of
apoptosis of EPCs. Additionally, silent information regula-
tor type-1 (SIRT1), one of the sirtuin NAD-dependent
protein/histone deacetylase family, can promote the sur-
vival of EPCs by restraining p53- and non-p53-dependent
apoptosis in response to DNA damage and oxidative stress
[103]. Lastly, Sasi et al. [104] reported that TNF-TNFR2/
P75 signaling inhibits early but increases delayed non-
targeted effects in bone marrow-derived EPCs.Reduced sensitivity of EPCs to inflammatory activation
Previous studies have shown that, in the early stages, in-
flammatory factors can stimulate the activities of EPCs,
but a chronic inflammatory environment is harmful to
the survival and function of EPCs. Therefore, it is signifi-
cant to reduce the sensitivity of EPCs to chronic inflam-
matory activation.
As it has been established, TNF-alpha and IL-1-beta
are harmful to early EPCs, but Henrich et al. [105] eluci-
dated that simvastatin, a 3-hydroxy-3-methylglutaryl-co-
enzyme-A reductase inhibitor, can protect EPCs from
TNF-alpha-mediated and eventually from IL-1-beta-me-
diated apoptosis, which suggests that in a hyperinflam-
matory situation, simvastatin has protective effects on
the survival of EPCs. Another report posited that all
EPC subtypes release chemokines and thromboinflam-
matory mediators, which can be stimulated with TNF-
alpha. Early EPCs primarily release thromboinflamma-
tory mediators such as TF, but adult, late EPCs primarily
release chemokines such as monocyte chemoattractant
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statin. Zhang et al. [106] put forward that pharmacological
modulation of EPCs before and after transplantation
may benefit EPCs with regard to both function and
survival. Liu et al. [107] presented a novel idea to make
EPCs less sensitive to inflammatory stimuli, that before
therapy of ischemic diseases with EPCs, EPCs from
human umbilical cord blood are transduced with a
lentiviral vector for stable expression of A20, an anti-
inflammatory protein. Finally, Wang et al. [97] have
suggested that Ang-1-EPCs can alleviate inflammatory
responses induced by TNF-alpha in vitro, improve cell
survival, and promote the endothelialization of dam-
aged blood vessels.
To sum up, it is a great pleasure for us to see that
studies investigating the interactions between inflamma-
tory mediators and EPCs put forward novel approaches
to the therapy of ischemic stroke (Figure 8). However,
the role of other inflammatory factors on EPCs is still
unclear. In addition, the inflammatory stimuli have vary-
ing influences on EPCs in different periods; therefore,
determining specifically when and how to intervene withFigure 8 Novel EPC-based cell therapies are under development for ische
treating ischemic tissues, including the processes of a. mobilization, b. hom
EPCs source to treat ischemic stroke and myocardial infarction.regard to inflammatory stimuli still remains to be
explored.
Conclusions
As far as the role of EPCs on ischemic stroke is con-
cerned, we have analyzed extensively the progress and
existing problems in the related literature. Although it
has yet to be fully determined, the focus on immune
phenotypes of EPCs in ischemic stroke may enlighten us
by determining whether the combination of activating
different immune phenotypes can enhance EPCs’ impact
on ischemic stroke. Moreover, the time distribution and
quantitation of EPCs in ischemic stroke remain to be
perfected and standardized. Excitedly, our extensive dis-
cussions on EPC therapy provide significant evidence to
make a novel hypothesis that the inhibition of apoptosis
factors and activation of the protection factors may be
administrated in order to reduce negative-factor-
mediated EPC toxicities or enhance EPC levels for
improving EPC therapy. However, the mechanisms per-
taining to mobilization, migration, and endogenous re-
pair of EPCs after ischemic stroke need to be furthermic stroke and myocardial infarction. (A)The mechanisms of EPCs
ing, c. survival, and d. differentiation. (B) Cell therapy from iPSCs and
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tween angiogenesis and neurogenesis. Ultimately, this
ambiguity is in result of the relative lack of studies done
on EPC-based gene regulation, therapy, and the coincid-
ing disadvantages. In conclusion, the role of EPCs on is-
chemic stroke remains to be further determined.
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